Viatris Inc. (VTRS) Earnings
Viatris Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $0.63. VTRS has beaten EPS estimates in 6 of its last 12 reported quarters (average surprise -31.0% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $0.52 | $0.59 | +13.5% | $3.5B | +4.8% |
| Feb 26, 2026 | $0.52 | $-0.30 | -156.7% | $3.7B | +5.0% |
| Nov 6, 2025 | $0.62 | $0.67 | +7.9% | $3.8B | +3.8% |
| Aug 7, 2025 | $0.56 | $0.62 | +11.5% | $3.6B | +3.3% |
| May 8, 2025 | $0.49 | $0.50 | +1.6% | $3.3B | +0.6% |
| Feb 27, 2025 | $0.61 | $0.54 | -11.5% | $3.5B | -2.0% |
| Nov 7, 2024 | $0.68 | $0.75 | +10.8% | $3.7B | +0.6% |
| Aug 8, 2024 | $0.68 | $0.69 | +1.8% | $3.8B | +0.4% |
| May 9, 2024 | $0.67 | $0.67 | -0.4% | $3.7B | -0.7% |
| Feb 28, 2024 | $0.67 | $0.61 | -9.0% | $3.8B | -0.8% |
| Feb 27, 2023 | $0.72 | $0.67 | -6.9% | $3.9B | -2.9% |
| Feb 28, 2022 | $0.82 | $0.80 | -2.4% | $4.3B | -0.1% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Strong start to the year with total revenues of $3.5 billion, up 3% y/y, adjusted EBITDA of $1 billion, and adjusted EPS of 59 cents/share. - Commercial execution strong, with Greater China a significant contributor and Japan showing momentum with Effexor launch. - Pipeline progress: Regulatory approval for Effexor in Japan, on track for remaining five regulatory decisions in H2 2026, including weekly contraceptive patch and fast-acting MLOC scan. - Capital allocation: Disciplined approach, deploying capital balanced, returning to shareholders and investing in business. - Organization: Making progress on cost structure optimization, resource allocation, and operational efficiency.
Guidance
- Reaffirming guidance ranges. - Expect stronger growth in Greater China mid to high single digits and delayed competition for Ameteza in Japan, partially offset by supply constraints and competitive pressure. - If current foreign currency rates hold, incremental 1% tailwind on total revenues and adjusted EBITDA. - Total revenues, adjusted EBITDA, and adjusted EPS still weighted to second half. - Confident in meeting or exceeding expectations for the remainder of the year.
Segment performance
Developed markets: Net sales increased 1% y/y. North America grew 3% driven by estradiol, BRAINA, and complex generic launches. Europe declined ~1% due to softer market conditions, competitive pressure on DiMista, and supply constraints but had strong fundamentals. Emerging markets: Net sales flat y/y, below expectations, supported by established brands but offset by supply constraints in lower margin ARV portfolio. JANs: Net sales decreased ~2% y/y but above expectations, driven by competition in Australia and government price regulations in Japan, partially offset by key brands. Greater China: Grew 18% y/y, driven by aging population, increasing demand for cardiovascular products, strategic selling and marketing investments, and e-commerce growth where sales more than doubled.
Risks & headwinds
- Policy risk in China being dynamic and unpredictable. - Supply constraints in lower margin ARV portfolio. - Competitive pressure in certain markets like Australia and Japan.
Analyst Q&A
Q: Glenn Santangelo asked about stability of China growth, commercial efforts, and pipeline opportunities.
A: Scott and Philippe discussed strong China performance due to market and team, policy risk monitoring, and key pipeline opportunities like estrogen patch, fast-acting meloxicam, Cenarimod, etc.
Q: Umar Rafat asked about free cash flow and salatagrel trial endpoint.
A: Paul talked about cash flow drivers, Philippe explained salatagrel trial endpoint as ranking severity of MRI.
Q: Matt Delatore asked about meloxicam priority review, label, and cost savings.
A: Philippe discussed meloxicam regulatory timeline and label expectations, Paul talked about cost savings progress.
Q: Les Salewski asked about new product revenue, BD, and CFO transition.
A: Scott discussed new product revenue, BD focus on in-market accretive assets, and CFO transition with Paul.
Q: Jason Gerberry asked about fast-acting meloxicam Salesforce strategy.
A: Karine discussed specialty Salesforce strategy.
Q: David Amselen asked about innovative business in US and in-licensings.
A: Scott discussed leveraging therapeutic verticals and in-licensing approach.
Q: Ethan asked about generic semaglutide and ARV business supply constraints.
A: Philippe discussed GLP-1 strategy and ARV supply constraint mitigation.
Q: Ash Verma asked about 4% growth goal.
A: Scott discussed 4% growth goal by 2030 and progress towards it